Shares of Ecolab Inc (NYSE: ECL) were rising in early trading on Wednesday.
The downside risk to the company’s earnings seems “relatively benign,” given its business model and strategy, according to Piper Sandler.
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."
Intel Corp (INTC) is a leading technology company, but stock performance has faced challenges. Analyst sees potential in new segment and long-term targets.